Related Experiment Video
Updated: Feb 27, 2026
10:29
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
2.5K
HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: SAR and Lead Optimization Using CoMFA and CoMSIA Studies
Murugesan Vanangamudi1, Vasanthanathan Poongavanam2, Vigneshwaran Namasivayam3
1Department of Medicinal and Pharmaceutical Chemistry, Sree Vidyanikethan College of Pharmacy, Tirupati, Andhra Pradesh - 517102, India.
Current Medicinal Chemistry
|July 8, 2017
Summary
This review summarizes 3D-QSAR strategies for optimizing non-nucleoside reverse transcriptase inhibitors (NNRTIs) against HIV-1. These methods aid in designing new drugs to combat resistant HIV-1 reverse transcriptase variants.
Area of Science:
- Medicinal Chemistry
- Computational Chemistry
- Drug Design
Background:
- HIV-1 reverse transcriptase (RT) inhibitors are crucial for HIV treatment.
- Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are effective but face resistance.
- Drug-resistant HIV-1 RT variants necessitate novel inhibitor design strategies.
Purpose of the Study:
- To review lead optimization strategies for NNRTIs using 3D-QSAR studies.
- To cover NNRTI research from 1995 to 2016.
- To explore structure-activity relationships and guide future drug design.
Main Methods:
- Utilized conformation-dependent alignment-based 3D-QSAR methods (CoMFA and CoMSIA).
- Analyzed diverse NNRTI chemotypes including thiazolobenzimidazoles and thiadiazines.
- Investigated functional group positions influencing protein-ligand interactions.
Main Results:
- 3D-QSAR studies (CoMFA, CoMSIA) align with structure-based methods for lead optimization.
- Molecular docking and interaction fingerprints elucidated common binding modes.
- Structure-activity relationships (SAR) provide insights into NNRTI efficacy.
Conclusions:
- This review highlights protein-ligand interactions and SAR for NNRTI chemotypes.
- Understanding these interactions aids in designing novel, potent NNRTI candidates.
- Provides a foundation for medicinal chemists to develop next-generation HIV therapies.
Related Concept Videos
01:10Retrovirus Life Cycles
50.0K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.0K
02:33Retroviruses
15.1K
Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
15.1K